Clinical efficacy and adverse reactions of dexamethasone combined with ademetionine in the treatment of intrahepatic cholestasis of pregnancy

Abstract

The purpose of the study was to investigate the clinical efficacy and adverse reactions of dexamethasone combined with ademetionine in the treatment of intrahepatic cholestasis of pregnancy (ICP). Ninety-four patients with ICP admitted to our hospital from February 2018 to February 2019 were selected and were randomly divided into control group (n=47) and experimental group (n=47). Among them, the patients in the control group were treated with routine ademetionine for therapeutic intervention, while the patients in the experimental group were treated with dexamethasone combined with ademetionine. After that, the clinical efficacy, and adverse reactions of these two treatment methods were compared between the two groups. The pruritus scores of the patients in the two groups after treatment were significantly lower than those before treatment, and the scores in the experimental group were significantly lower than those in the control group. The levels of liver function indexes such as AST, ALT and TBA in both groups after treatment were significantly lower than those before treatment, and the levels in the experimental group were significantly lower than those in the control group. The levels of proinflammatory cytokines such as IL-12 and TNF-α in both groups after treatment were lower than those before treatment, and those levels after treatment in the experimental group were significantly lower than those in the control group, with statistically significant differences (all P < 05). There were no adverse reactions such as nausea, vomiting, abdominal pains, etc. occurring in the two groups during the treatment. Patients’ electrocardiogram and blood and urine routine examination results were normal and medication safety was ensured. Dexamethasone combined with ademetionine can effectively relieve pruritus, reduce the levels of proinflammatory cytokines and improve liver function indexes, with no obvious adverse reactions in the treatment, which is worthy of application and promotion in the clinical practice.